Savara announces expanded access program (eap) for molgramostim inhalation solution (molgramostim) for patients with autoimmune pulmonary alveolar proteinosis (apap)

Langhorne, pa.--(business wire)--savara inc. (nasdaq: svra) (the company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the savara early access program, a molgramostim expanded access program (eap) for patients with apap. the program enables physicians to request molgramostim for eligible apap patients in select geographies where the product is not commercially available and in compliance with local regulatory requirements. the savara early ac.
SVRA Ratings Summary
SVRA Quant Ranking